225 related articles for article (PubMed ID: 28744948)
21. Overexpression of periostin in stroma positively associated with aggressive prostate cancer.
Tian Y; Choi CH; Li QK; Rahmatpanah FB; Chen X; Kim SR; Veltri R; Chia D; Zhang Z; Mercola D; Zhang H
PLoS One; 2015; 10(3):e0121502. PubMed ID: 25781169
[TBL] [Abstract][Full Text] [Related]
22. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.
Hashimoto Y; Skacel M; Adams JC
BMC Cancer; 2008 Jun; 8():185. PubMed ID: 18590537
[TBL] [Abstract][Full Text] [Related]
23. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.
Webber JP; Spary LK; Mason MD; Tabi Z; Brewis IA; Clayton A
Oncotarget; 2016 Apr; 7(15):20124-39. PubMed ID: 26934553
[TBL] [Abstract][Full Text] [Related]
24. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
Contreras HR; Ledezma RA; Vergara J; Cifuentes F; Barra C; Cabello P; Gallegos I; Morales B; Huidobro C; Castellón EA
Urol Oncol; 2010; 28(5):534-40. PubMed ID: 19450993
[TBL] [Abstract][Full Text] [Related]
25. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Ambrosio MR; Di Serio C; Danza G; Rocca BJ; Ginori A; Prudovsky I; Marchionni N; Del Vecchio MT; Tarantini F
Diagn Pathol; 2016 May; 11(1):45. PubMed ID: 27225200
[TBL] [Abstract][Full Text] [Related]
26. Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer.
Poblete CE; Fulla J; Gallardo M; Muñoz V; Castellón EA; Gallegos I; Contreras HR
Int J Oncol; 2014 Mar; 44(3):647-54. PubMed ID: 24424718
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of syndecan-1 expression in human endometrial cancer.
Hasengaowa ; Kodama J; Kusumoto T; Shinyo Y; Seki N; Hiramatsu Y
Ann Oncol; 2005 Jul; 16(7):1109-15. PubMed ID: 15851381
[TBL] [Abstract][Full Text] [Related]
28. Expression and prognostic role of syndecan-2 in prostate cancer.
Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
[TBL] [Abstract][Full Text] [Related]
29. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
[TBL] [Abstract][Full Text] [Related]
30. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
31. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
32. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
33. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
36. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.
Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ
Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510
[TBL] [Abstract][Full Text] [Related]
37. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
38. Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation.
Sakko AJ; Ricciardelli C; Mayne K; Dours-Zimmermann MT; Zimmermann DR; Neufing P; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2007 Feb; 67(3):288-300. PubMed ID: 17192879
[TBL] [Abstract][Full Text] [Related]
39. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
[TBL] [Abstract][Full Text] [Related]
40. Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.
Martini C; Logan JM; Sorvina A; Gordon C; Beck AR; S-Y Ung B; Caruso MC; Moore C; Hocking A; Johnson IRD; Li KL; Karageorgos L; Hopkins AM; Esterman AJ; Huzzell C; Brooks RD; Lazniewska J; Hickey SM; Bader C; Parkinson-Lawrence E; Weigert R; Sorich MJ; Tewari P; Martin C; O'Toole S; Bates M; Ward M; Mohammed B; Keegan H; Watson W; Prendergast S; Heffernan S; NiMhaolcatha S; O'Connor R; Malone V; Carter M; Ryan K; Brady N; Clarke A; Sokol F; Prabhakaran S; Stahl J; Klebe S; Samaratunga H; Delahunt B; Selemidis S; Moretti KL; Butler LM; O'Leary JJ; Brooks DA
Pathology; 2023 Feb; 55(1):40-51. PubMed ID: 36089417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
